

GENERAL INFORMATION

LOCATION

Hof ter Musschen
Av. Emmanuel Mounierlaan 2
1200 Brussel
Tel: 02 774 01 10

TARGET AUDIENCE

The target audience for this symposium consists out of: hematologists, hematology nurses, hematologists in training and other physicians interested.

REGISTRATION

Please register online via the BHS website (www.bhs.be), or via the calendar at www.congresscare.com
Registration is free of charge.

LANGUAGE

The meeting language will be English.

ACCREDITATION

Accreditation is pending.

WEBSITE

www.bhs.be



BHS

Belgian Hematology Society

Symposium MINIMAL RESIDUAL DISEASE (MRD) IN MULTIPLE MYELOMA: FACTS AND FUTURE

BHS Society Office

Congress Care
P.O. Box 440
5201 AK 's-Hertogenbosch
The Netherlands
bhs@congresscare.com
www.congresscare.com



Announcement

FRIDAY 23 NOVEMBER 2018

Hof ter Musschen, Brussels

www.bhs.be

INTRODUCTION

The therapeutic landscape of multiple myeloma has dramatically changed over the last years and is still in continuous evolution. Second-generation proteasome inhibitors, new immunomodulatory drugs and monoclonal antibodies have improved the outcome of myeloma patients and can be given in various combinations at different stages of the disease. Good knowledge on how to prevent and manage the side effects of these agents is crucial to maximize their therapeutic benefit and preserve the quality of life of patients.

We welcome physicians and nurses treating myeloma patients and those indirectly involved in myeloma care on this symposium dedicated to prevention and management of adverse events.

Michel Delforge, committee chair

COMMITTEE MEMBERS:

Chairman: Michel Delforge

Karolien Beel	Nathalie Meuleman
Greet Bries	Philippe Mineur
Jo Caers	Fritz Offner
Bernard De Prijck	Rik Schots
Hade De Samblanx	Ann Van de Velde
Michel Delforge	Jan Van Droogenbroeck
Hilde Demuyne	Isabelle Vande Broek
Anne Deweweire	Mélanie Vaes
Chantal Doyen	Marie-Christiane Vekemans
Caroline Jacquy	Philip Vlumens
Karel Fostier	Kalung Wu
Alain Kentos	

PROGRAMME

FRIDAY 23 November 2018

Chairs: *Michel Delforge & Marie-Christiane Vekemans*

- 14:00** **Welcome and Introduction**
Michel Delforge (UZ Leuven)
- 14:20 **Monitoring of MRD by flow cytometry**
Bruno Paiva (University of Navarra, Spain)
- 15:00 Discussion
- 15:20 **Monitoring of MRD by genetic analyses**
Marleen Bakkus (University of Brussels)
- 16:00 Discussion
- 16:15** **Coffee break**
- 16:45 **Monitoring of MRD by PET scan**
Nadia Withofs (University Hospital of Liège)
- 17:15 **Panel discussion**
Moderators: *Marie-Christiane Vekemans and Jo Caers*
- 17:45 **Closing remarks**
Michel Delforge (UZ Leuven)
- 18:00** **Reception**